Due diligence and negotiations are in progress for the acquisition and rights to develop other promising early stage compounds. Typically, Avicenna seeks to add atleast two compounds every year into its pipeline. The due diligence process ensures thorough evaluation and risk assessment prior to acquisition and hence, Avicenna believes in a higher probability of success for its acquired compounds compared to present pharma industry standards.